IKK is a therapeutic target in KRAS-induced lung cancer with disrupted p53 activity

Abstract excerpt

Activating mutations in KRAS are prevalent in cancer, but therapies targeted to oncogenic RAS have been ineffective to date. These results argue that targeting downstream effectors of RAS will be an alternative route for blocking RAS-driven oncogenic pathways. We and others have shown that oncogenic RAS activates the NF-κB transcription factor pathway and that KRAS-induced lung tumorigenesis is suppressed by...

Topics

Join the communities discussing this publication.

• Cytokine Signaling Pathways and Interactions
• interferon and immune responses
• NF-κB Signaling Pathways